Eisaku Miyauchi

13PUBLICATIONS
84CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRadiation therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 27, 2026
Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

|Apr 21, 2026
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

|Dec 11, 2025
Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).

Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi

|Nov 17, 2024
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.

Takaaki Fujimura, Koh Furugaki, Hayato Mizuta

|Sep 09, 2023
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.

Kana Watanabe, Ryota Saito, Eisaku Miyauchi

|Aug 17, 2023
Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.

Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi

Pageof 3

Frequent Collaborators

2 joint publications

Hiroshige Yoshioka

2 joint publications

Eiki Kikuchi

2 joint publications

Ryoko Saito

2 joint publications

Makoto Nishio